- Home
- CBIO vs SUJA Comparison
CBIO vs SUJA Comparison
Compare CBIO & SUJA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CBIO | SUJA |
|---|---|---|
| Founded | 2003 | N/A |
| Country | United States | United States |
| Employees | 44 | N/A |
| Industry | | Beverages (Production/Distribution) |
| Sector | | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 482.6M | 426.8M |
| IPO Year | N/A | 2026 |
Fundamental Metrics
Financial Performance| Metric | CBIO | SUJA |
|---|---|---|
| Price | $16.86 | $10.92 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $26.67 | N/A |
| AVG Volume (30 Days) | ★ 313.1K | 262.1K |
| Earning Date | 04-29-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $279.20 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.72 | $8.71 |
| 52 Week High | $27.41 | $11.02 |
Technical Indicators
Market Signals| Indicator | CBIO | SUJA |
|---|---|---|
| Relative Strength Index (RSI) | 42.88 | 72.92 |
| Support Level | $17.02 | N/A |
| Resistance Level | $19.05 | N/A |
| Average True Range (ATR) | 1.26 | 0.91 |
| MACD | -0.01 | 0.15 |
| Stochastic Oscillator | 21.77 | 90.91 |
Price Performance
Historical ComparisonAbout CBIO Crescent Biopharma Inc.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.